LifeWealth Investments LLC Takes $229,000 Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• LifeWealth Investments LLC has acquired a new stake in Thermo Fisher Scientific, purchasing 565 shares valued at approximately $229,000 in the second quarter.
• Thermo Fisher Scientific's recent earnings report showed $5.79 earnings per share, exceeding analysts' expectations and demonstrating a 4.9% year-over-year revenue increase.
• The stock's current market capitalization stands at $215.97 billion, and it has a consensus target price of $595.75 from 19 equities research analysts rating it as a "Buy."

LifeWealth Investments LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 565 shares of the medical research company's stock, valued at approximately $229,000.

Several other institutional investors have also modified their holdings of TMO. Nuveen LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $532,360,000. EdgePoint Investment Group Inc. bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $172,139,000. Cohen Investment Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 6,655.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock valued at $167,271,000 after purchasing an additional 331,180 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after purchasing an additional 329,974 shares in the last quarter. Finally, Auto Owners Insurance Co lifted its holdings in shares of Thermo Fisher Scientific by 6,773.5% during the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company's stock valued at $143,309,000 after purchasing an additional 283,810 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 0.8%

NYSE:TMO opened at $571.94 on Friday. The firm has a market capitalization of $215.97 billion, a price-to-earnings ratio of 33.04, a price-to-earnings-growth ratio of 3.25 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The stock's 50 day moving average price is $502.38 and its two-hundred day moving average price is $452.23. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. The firm had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business's quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Wells Fargo & Company lifted their price objective on Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an "overweight" rating in a report on Thursday. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. Finally, Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of Thermo Fisher Scientific in a research note on Thursday. Nineteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $595.75.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,666 shares of company stock worth $13,990,971 over the last three months. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.